Hookipa Pharma (HOOK) was downgraded to a Hold Rating at Citi
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2025
0mins
Source: Business Insider
Analyst Rating and Price Target: Hookipa Pharma received a Hold rating from Citi analyst Sean Lee, with a price target of $4.50, while its shares closed at $2.15.
Company Overview: Hookipa Pharma specializes in developing immunotherapeutics for infectious diseases and cancers using its proprietary arenavirus platform, with products designed to enhance the immune response.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
